Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging

Glycogen synthase kinase-3 (GSK-3) is associated with various key biological processes, including glucose regulation, apoptosis, protein synthesis, cell signaling, cellular transport, gene transcription, proliferation, and intracellular communication. Accordingly, GSK-3 has been implicated in a wide variety of diseases and specifically targeted for both therapeutic and imaging applications by a large number of academic laboratories and pharmaceutical companies. Here, we review the structure, function, expression levels, and ligand-binding properties of GSK-3 and its connection to various diseases. A selected list of highly potent GSK-3 inhibitors, with IC50 <20 nM for adenosine triphosphate (ATP)-competitive inhibitors and IC50 <5 μM for non-ATP-competitive inhibitors, were analyzed for structure activity relationships. Furthermore, ubiquitous expression of GSK-3 and its possible impact on therapy and imaging are also highlighted. Finally, a rational perspective and possible route to selective and effective GSK-3 inhibitors is discussed.

[1]  G. Koning,et al.  A Novel 111In-Labeled Anti–Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[2]  Steven H. Liang,et al.  Discovery of [11C]PF-367 for neuroimaging of glycogen synthase kinase 3 , 2015 .

[3]  Young T. Hong,et al.  Synthesis and Initial in Vivo Studies with [(11)C]SB-216763: The First Radiolabeled Brain Penetrative Inhibitor of GSK-3. , 2015, ACS medicinal chemistry letters.

[4]  A. Ströhle,et al.  Prescription Patterns of Psychotropic Medications for the Treatment of Psychotic Disorders in the Largest Mental Health Institutions of Uganda , 2014, Journal of clinical psychopharmacology.

[5]  A. Hannan,et al.  Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain. , 2014, Human molecular genetics.

[6]  X. Shao,et al.  Synthesis and evaluation of [(11)C]PyrATP-1, a novel radiotracer for PET imaging of glycogen synthase kinase-3β (GSK-3β). , 2014, Nuclear medicine and biology.

[7]  M. Mohutsky,et al.  Investigational Small-Molecule Drug Selectively Suppresses Constitutive CYP2B6 Activity at the Gene Transcription Level: Physiologically Based Pharmacokinetic Model Assessment of Clinical Drug Interaction Risk , 2014, Drug Metabolism and Disposition.

[8]  Gi Fay Mok,et al.  Smad1 transcription factor integrates BMP2 and Wnt3a signals in migrating cardiac progenitor cells , 2014, Proceedings of the National Academy of Sciences.

[9]  X. Shao,et al.  Radiosynthesis of [11C]PyrATP1, a novel radiotracer targeting the ATP-binding site of GSK-3{beta} , 2014 .

[10]  Stephen L. Abrams,et al.  GSK-3 as potential target for therapeutic intervention in cancer , 2014, Oncotarget.

[11]  J. DeFelipe,et al.  Selective alterations of neurons and circuits related to early memory loss in Alzheimer’s disease , 2014, Front. Neuroanat..

[12]  E. Tolosa,et al.  A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy , 2014, Movement disorders : official journal of the Movement Disorder Society.

[13]  H. Huppertz,et al.  Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial , 2014, Movement disorders : official journal of the Movement Disorder Society.

[14]  P. Brauns-Schubert,et al.  GSK-3 – at the crossroads of cell death and survival , 2014, Journal of Cell Science.

[15]  Wei Chen,et al.  Association of glycogen synthase kinase-3β with Parkinson’s disease (Review) , 2014, Molecular medicine reports.

[16]  C. Keller,et al.  Glycogen synthase kinase 3 inhibitors induce the canonical WNT/β-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma , 2014, Proceedings of the National Academy of Sciences.

[17]  M. Donowitz,et al.  AKT and GSK-3 Are Necessary for Direct Ezrin Binding to NHE3 as Part of a C-terminal Stimulatory Complex , 2014, The Journal of Biological Chemistry.

[18]  A. Sawa,et al.  Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application , 2014, Translational Psychiatry.

[19]  M. Pardo,et al.  Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments. , 2014, Pharmacology & therapeutics.

[20]  M. Taha,et al.  Naproxen and Cromolyn as New Glycogen Synthase Kinase 3β Inhibitors for Amelioration of Diabetes and Obesity: An Investigation by Docking Simulation and Subsequent In Vitro/In Vivo Biochemical Evaluation , 2013, Journal of biochemical and molecular toxicology.

[21]  Weiping Liu,et al.  Parkinson's Disease-Associated Dj-1 Mutations Increase Abnormal Phosphorylation of Tau Protein through Akt/Gsk-3β Pathways , 2013, Journal of Molecular Neuroscience.

[22]  Hong-Zhuan Chen,et al.  Activation of muscarinic receptors inhibits glutamate-induced GSK-3β overactivation in PC12 cells , 2013, Acta Pharmacologica Sinica.

[23]  Shanshan Ma,et al.  GSK‐3α/β‐mediated phosphorylation of CRMP‐2 regulates activity‐dependent dendritic growth , 2013, Journal of neurochemistry.

[24]  M. Vázquez-Carrera,et al.  Glucose dependence of glycogen synthase activity regulation by GSK3 and MEK/ERK inhibitors and angiotensin-(1-7) action on these pathways in cultured human myotubes. , 2013, Cellular signalling.

[25]  K. Cassidy,et al.  Pharmacokinetics, Metabolism, and Excretion of the Glycogen Synthase Kinase-3 Inhibitor LY2090314 in Rats, Dogs, and Humans: A Case Study in Rapid Clearance by Extensive Metabolism with Low Circulating Metabolite Exposure , 2013, Drug Metabolism and Disposition.

[26]  J. DeFelipe,et al.  Alzheimer disease-like cellular phenotype of newborn granule neurons can be reversed in GSK-3β-overexpressing mice , 2013, Molecular Psychiatry.

[27]  C. Pérez,et al.  Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. , 2013, ACS chemical neuroscience.

[28]  J. DeFelipe,et al.  GSK-3β overexpression causes reversible alterations on postsynaptic densities and dendritic morphology of hippocampal granule neurons in vivo , 2013, Molecular Psychiatry.

[29]  M. Wiśniewska Physiological Role of β-Catenin/TCF Signaling in Neurons of the Adult Brain , 2013, Neurochemical Research.

[30]  F. J. Luque,et al.  Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. , 2013, European journal of medicinal chemistry.

[31]  Shou-Jiang Gao,et al.  HIV-1 Tat Promotes Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) vIL-6-Induced Angiogenesis and Tumorigenesis by Regulating PI3K/PTEN/AKT/GSK-3β Signaling Pathway , 2013, PloS one.

[32]  David J. Fleet,et al.  Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. , 2012, Journal of Alzheimer's disease : JAD.

[33]  P. Blower,et al.  World Molecular Imaging Congress , 2013 .

[34]  Yongbing Chen,et al.  [Judging the postoperative lymph node metastasis of esophagus cancer patients with pN0 stage by detecting MTA1 protein expression]. , 2012, Zhonghua yi xue za zhi.

[35]  R. Jope,et al.  Glycogen synthase kinase‐3 levels and phosphorylation undergo large fluctuations in mouse brain during development , 2012, Bipolar disorders.

[36]  M. Svensson,et al.  Imidazopyridine‐Based Inhibitors of Glycogen Synthase Kinase 3: Synthesis and Evaluation of Amide Isostere Replacements of the Carboxamide Scaffold , 2012, Chemistry & biodiversity.

[37]  Mark Denham,et al.  Glycogen Synthase Kinase 3β and Activin/Nodal Inhibition in Human Embryonic Stem Cells Induces a Pre-Neuroepithelial State That Is Required for Specification to a Floor Plate Cell Lineage , 2012, Stem cells.

[38]  M. Carducci,et al.  Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics , 2012, Investigational New Drugs.

[39]  C. So,et al.  Selective treatment of mixed-lineage leukemia leukemic stem cells through targeting glycogen synthase kinase 3 and the canonical Wnt/&bgr;-catenin pathway , 2012, Current opinion in hematology.

[40]  Shih-ku Lin,et al.  Carbamazepine treatment of bipolar disorder: a retrospective evaluation of naturalistic long-term outcomes , 2012, BMC Psychiatry.

[41]  Sven Hellberg,et al.  Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimer's disease: design, synthesis, and characterization of pyrazines. , 2012, Journal of medicinal chemistry.

[42]  V. Palomo,et al.  5-Imino-1,2-4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3β (GSK-3β) and phosphodiesterase 7 (PDE7) inhibitors: determination of blood-brain barrier penetration and binding to human serum albumin. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[43]  Alan A. Wilson,et al.  Towards the preparation of radiolabeled 1-aryl-3-benzyl ureas: Radiosynthesis of [(11)C-carbonyl] AR-A014418 by [(11)C]CO(2) fixation. , 2012, Bioorganic & medicinal chemistry letters.

[44]  J. Roder,et al.  Synergistic interactions between PDE4B and GSK-3: DISC1 mutant mice , 2012, Neuropharmacology.

[45]  C. Pérez,et al.  5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3. , 2012, Journal of medicinal chemistry.

[46]  J. Beaulieu,et al.  Molecular Neuroscience Review Article Gsk-3 and Wnt Signaling in Neurogenesis and Bipolar Disorder , 2022 .

[47]  J. Beaulieu,et al.  Inhibition of GSK3 by lithium, from single molecules to signaling networks , 2012, Front. Mol. Neurosci..

[48]  C. Pérez,et al.  Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities. , 2011, Journal of medicinal chemistry.

[49]  Mindy I. Davis,et al.  Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.

[50]  Ana Martínez,et al.  GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS , 2011, Front. Mol. Neurosci..

[51]  Theonie Anastassiadis,et al.  Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity , 2011, Nature biotechnology.

[52]  E. Beurel Regulation by Glycogen Synthase Kinase-3 of Inflammation and T Cells in CNS Diseases , 2011, Front. Mol. Neurosci..

[53]  L. Ivashkiv,et al.  Tumor necrosis factor induces GSK3 kinase–mediated cross-tolerance to endotoxin in macrophages , 2011, Nature Immunology.

[54]  C. Sutherland What Are the bona fide GSK3 Substrates? , 2011, International journal of Alzheimer's disease.

[55]  F. J. Luque,et al.  Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds. , 2011, Journal of medicinal chemistry.

[56]  O. Forlenza,et al.  Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial , 2011, British Journal of Psychiatry.

[57]  M. Guarnieri,et al.  A high-throughput TNP-ATP displacement assay for screening inhibitors of ATP-binding in bacterial histidine kinases. , 2011, Assay and drug development technologies.

[58]  Gernot Frenking,et al.  Structurally sophisticated octahedral metal complexes as highly selective protein kinase inhibitors. , 2011, Journal of the American Chemical Society.

[59]  Matthew D. Wessel,et al.  6-amino-4-(pyrimidin-4-yl)pyridones: novel glycogen synthase kinase-3β inhibitors. , 2011, Bioorganic & medicinal chemistry letters.

[60]  A. Oro,et al.  Cell Migration: GSK3β Steers the Cytoskeleton's Tip , 2011, Cell.

[61]  J. Woodgett,et al.  Tissue-Specific Analysis of Glycogen Synthase Kinase-3α (GSK-3α) in Glucose Metabolism: Effect of Strain Variation , 2011, PloS one.

[62]  G. Hutchins,et al.  The first synthesis of [(11)C]SB-216763, a new potential PET agent for imaging of glycogen synthase kinase-3 (GSK-3). , 2011, Bioorganic & medicinal chemistry letters.

[63]  Humberto González-Díaz,et al.  First computational chemistry multi-target model for anti-Alzheimer, anti-parasitic, anti-fungi, and anti-bacterial activity of GSK-3 inhibitors in vitro, in vivo, and in different cellular lines , 2011, Molecular Diversity.

[64]  Gangchun Wang,et al.  Regulation of glycogen synthase kinase-3 during bipolar mania treatment. , 2010, Bipolar disorders.

[65]  Alan A. Wilson,et al.  Radiolabeled Small Molecule Protein Kinase Inhibitors for Imaging with PET or SPECT , 2010, Molecules.

[66]  R. Jope,et al.  Glycogen synthase kinase-3 regulates inflammatory tolerance in astrocytes , 2010, Neuroscience.

[67]  Eun-Mi Hur,et al.  GSK3 signalling in neural development , 2010, Nature Reviews Neuroscience.

[68]  I. García,et al.  Using Topological Indices to Predict Anti-Alzheimer and Anti-Parasitic GSK-3 Inhibitors by Multi-Target QSAR in Silico Screening , 2010, Molecules.

[69]  P. Verhoest,et al.  Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010, ACS chemical neuroscience.

[70]  F. Gaunitz,et al.  4-Aminoethylamino-emodin – a novel potent inhibitor of GSK-3β– acts as an insulin-sensitizer avoiding downstream effects of activated β-catenin , 2009, Journal of cellular and molecular medicine.

[71]  Li-xiang Lin,et al.  Regulation of GSK-3 beta in the proliferation and apoptosis of human thyrocytes investigated using a GSK-3 beta-targeting RNAi adenovirus expression vector: involvement the Wnt/beta-catenin pathway , 2010, Molecular Biology Reports.

[72]  P. S. Klein,et al.  Validating GSK3 as an in vivo target of lithium action. , 2009, Biochemical Society transactions.

[73]  T. Gómez-Isla,et al.  A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo , 2009, Neurobiology of Disease.

[74]  H. Möller,et al.  Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. , 2009, The Journal of clinical psychiatry.

[75]  Ian Collins,et al.  Measuring and interpreting the selectivity of protein kinase inhibitors , 2009, Journal of chemical biology.

[76]  J. Walling,et al.  A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas , 2009, Clinical Cancer Research.

[77]  S. Hellberg,et al.  A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. , 2009, The Journal of clinical investigation.

[78]  M. Oya,et al.  GSK-3 IS A POTENTIAL THERAPEUTIC TARGET FOR THE TREATMENT OF RENAL CELL CARCINOMA (RCC): PRECLINICAL IN VITRO AND IN VIVO INVESTIGATION , 2009 .

[79]  J. Kunitomo,et al.  Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta. , 2009, Bioorganic & medicinal chemistry.

[80]  P. Cohen Guidelines for the effective use of chemical inhibitors of protein function to understand their roles in cell regulation. , 2009, The Biochemical journal.

[81]  B. Doble,et al.  Tissue-Specific Role of Glycogen Synthase Kinase 3β in Glucose Homeostasis and Insulin Action , 2008, Molecular and Cellular Biology.

[82]  S. Lovestone,et al.  A feasibility and tolerability study of lithium in Alzheimer's disease , 2008, International journal of geriatric psychiatry.

[83]  M. Portella,et al.  Long-term stability of cognitive impairment in bipolar disorder: a 2-year follow-up study of lithium-treated euthymic bipolar patients. , 2008, The Journal of clinical psychiatry.

[84]  Simon Lovestone,et al.  The GSK3 hypothesis of Alzheimer's disease , 2008, Journal of neurochemistry.

[85]  CRP CHD Genetics Collaboration,et al.  Collaborative pooled analysis of data on C-reactive protein gene variants and coronary disease: judging causality by Mendelian randomisation , 2008, European Journal of Epidemiology.

[86]  Yong Eun Kim,et al.  Design and synthesis of 7-hydroxy-1H-benzoimidazole derivatives as novel inhibitors of glycogen synthase kinase-3beta. , 2007, Bioorganic & medicinal chemistry letters.

[87]  Ana Martínez,et al.  Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease. , 2007, Journal of natural products.

[88]  M. Ding,et al.  The role of glycogen synthase kinase 3beta in the transformation of epidermal cells. , 2007, Cancer research.

[89]  O. Forlenza,et al.  Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder , 2007, British Journal of Psychiatry.

[90]  B. Doble,et al.  Glycogen synthase kinase 3, circadian rhythms, and bipolar disorder: a molecular link in the therapeutic action of lithium , 2007, Journal of circadian rhythms.

[91]  H. Gendelman,et al.  Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS. , 2007, Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology.

[92]  R. Jope,et al.  Glycogen Synthase Kinase-3 (GSK3): Inflammation, Diseases, and Therapeutics , 2007, Neurochemical Research.

[93]  H. Gendelman,et al.  Glycogen Synthase Kinase 3 Beta (GSK-3β) as a Therapeutic Target in NeuroAIDS , 2007, Journal of Neuroimmune Pharmacology.

[94]  A. Xu,et al.  Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. , 2006, Cancer research.

[95]  N. Kay,et al.  Inhibition of GSK-3 Induces Apoptosis of CLL Cells by Abrogating NFkB Nuclear Activity. , 2006 .

[96]  S. Mudaliar,et al.  Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue. , 2006, American journal of physiology. Endocrinology and metabolism.

[97]  B. Tekwani,et al.  Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases. , 2006, Journal of natural products.

[98]  S. A. Thomson,et al.  Synthesis and evaluation of novel heterocyclic inhibitors of GSK-3. , 2006, Bioorganic & medicinal chemistry letters.

[99]  D. Alonso,et al.  Marine Compounds as a New Source for Glycogen Synthase Kinase 3 Inhibitors , 2006 .

[100]  A. Ougolkov,et al.  Targeting GSK-3: a promising approach for cancer therapy? , 2006, Future oncology.

[101]  H. Wu,et al.  PTEN and GSK3β: key regulators of progression to androgen-independent prostate cancer , 2006, Oncogene.

[102]  H. Wu,et al.  PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. , 2006, Oncogene.

[103]  Alan A. Wilson,et al.  Synthesis and ex vivo evaluation of carbon-11 labelled N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea ([11C]AR-A014418): a radiolabelled glycogen synthase kinase-3beta specific inhibitor for PET studies. , 2005, Bioorganic & medicinal chemistry letters.

[104]  R. Campbell,et al.  The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts , 2005 .

[105]  R. Cardiff,et al.  Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis. , 2005, Cancer research.

[106]  G. Mills,et al.  Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. , 2005, Cancer research.

[107]  Brian Cunningham,et al.  The development of potent and selective bisarylmaleimide GSK3 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[108]  G. Agam,et al.  Low GSK-3β in schizophrenia as a consequence of neurodevelopmental insult , 2005, European Neuropsychopharmacology.

[109]  J. Kuemmerle Endogenous IGF-I protects human intestinal smooth muscle cells from apoptosis by regulation of GSK-3 beta activity. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[110]  P. Greengard,et al.  Pharmacological inhibitors of glycogen synthase kinase 3. , 2004, Trends in pharmacological sciences.

[111]  S. A. Thomson,et al.  Novel GSK-3 Inhibitor with Improved Cellular Activity. , 2004 .

[112]  S. Wahyuono,et al.  New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases. , 2004, Journal of medicinal chemistry.

[113]  R. Campbell,et al.  Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3. , 2004, Journal of medicinal chemistry.

[114]  Michel Goedert,et al.  GSK3 inhibitors: development and therapeutic potential , 2004, Nature Reviews Drug Discovery.

[115]  S. A. Thomson,et al.  Novel pyrazolopyrimidine derivatives as GSK-3 inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[116]  S. A. Thomson,et al.  Novel GSK-3 inhibitors with improved cellular activity. , 2004, Bioorganic & medicinal chemistry letters.

[117]  Kirk W. Johnson,et al.  Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. , 2004, Current pharmaceutical design.

[118]  R. Hill,et al.  The manzamine alkaloids. , 2004, The Alkaloids. Chemistry and biology.

[119]  R. Jope,et al.  Glycogen synthase kinase-3&bgr; is highly activated in nuclei and mitochondria , 2003, Neuroreport.

[120]  C. Pérez,et al.  Thienyl and phenyl alpha-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3beta) from a library of compound searching. , 2003, Journal of medicinal chemistry.

[121]  Claudia K Derian,et al.  Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3. , 2003, Bioorganic & medicinal chemistry letters.

[122]  R. Jope Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. , 2003, Trends in pharmacological sciences.

[123]  B. Doble,et al.  GSK-3: tricks of the trade for a multi-tasking kinase , 2003, Journal of Cell Science.

[124]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[125]  R. Eglen,et al.  A High-Throughput, Nonisotopic, Competitive Binding Assay for Kinases Using Nonselective Inhibitor Probes (ED-NSIP™) , 2002, Journal of biomolecular screening.

[126]  C. Pérez,et al.  First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. , 2002, Journal of medicinal chemistry.

[127]  R. Belmaker,et al.  GSK-3 and the neurodevelopmental hypothesis of schizophrenia , 2002, European Neuropsychopharmacology.

[128]  R. Jope,et al.  The multifaceted roles of glycogen synthase kinase 3β in cellular signaling , 2001, Progress in Neurobiology.

[129]  R. Jope,et al.  Proapoptotic Stimuli Induce Nuclear Accumulation of Glycogen Synthase Kinase-3β* , 2001, The Journal of Biological Chemistry.

[130]  R. Belmaker,et al.  Low GSK-3 activity in frontal cortex of schizophrenic patients , 2001, Schizophrenia Research.

[131]  P. Cohen,et al.  GSK3 takes centre stage more than 20 years after its discovery. , 2001, The Biochemical journal.

[132]  James R. Woodgett,et al.  Judging a Protein by More Than Its Name: GSK-3 , 2001, Science's STKE.

[133]  G. Fava,et al.  Cognitive-behavioral management of patients with bipolar disorder who relapsed while on lithium prophylaxis. , 2001, The Journal of clinical psychiatry.

[134]  P. Lochhead,et al.  Inhibition of GSK-3 Selectively Reduces Glucose-6-Phosphatase and Phosphoenolpyruvate Carboxykinase Gene Expression , 2001 .

[135]  P. Lochhead,et al.  Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and phosphoenolypyruvate carboxykinase gene expression. , 2001, Diabetes.

[136]  E. ter Haar,et al.  Structure of GSK3beta reveals a primed phosphorylation mechanism. , 2001, Nature structural biology.

[137]  J. Woodgett,et al.  Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation , 2000, Nature.

[138]  R. Belmaker,et al.  Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. , 2000, The American journal of psychiatry.

[139]  Gregory J. Parker,et al.  Development of High Throughput Screening Assays Using Fluorescence Polarization: Nuclear Receptor-Ligand-Binding and Kinase/Phosphatase Assays , 2000, Journal of biomolecular screening.

[140]  S. Mudaliar,et al.  Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. , 2000, Diabetes.

[141]  J. Woodgett,et al.  Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. , 2000, Nature.

[142]  P. Cohen,et al.  A GSK3‐binding peptide from FRAT1 selectively inhibits the GSK3‐catalysed phosphorylation of Axin and β‐catenin , 1999, FEBS letters.

[143]  R A Roth,et al.  The Role of Glycogen Synthase Kinase 3β in Insulin-stimulated Glucose Metabolism* , 1999, The Journal of Biological Chemistry.

[144]  M. Roussel,et al.  Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. , 1998, Genes & development.

[145]  Chris Sander,et al.  Objectively judging the quality of a protein structure from a Ramachandran plot , 1997, Comput. Appl. Biosci..

[146]  D. Melton,et al.  A molecular mechanism for the effect of lithium on development. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[147]  K. Imahori,et al.  Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[148]  J. Woodgett,et al.  Molecular cloning and expression of glycogen synthase kinase‐3/factor A. , 1990, The EMBO journal.

[149]  Philip R. Cohen,et al.  Multisite phosphorylation of glycogen synthase. Molecular basis for the substrate specificity of glycogen synthase kinase-3 and casein kinase-II (glycogen synthase kinase-5). , 1984, Biochimica et biophysica acta.

[150]  P. Cohen,et al.  Glycogen synthase kinase-3 from rabbit skeletal muscle. , 2005, Methods in enzymology.

[151]  P. Cohen,et al.  Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. , 1980, European journal of biochemistry.